基于CT的肝脏剩余体积及结局预测因素:不适合手术治疗并接受经动脉化疗栓塞的肝细胞癌患者
回顾性单臂单中心研究纳入41例接受经动脉化疗栓塞的肝细胞癌患者,基于基线多期CT计算肝脏剩余体积并与Child-Pugh、MELD、MELD-Na评分比较预测结局。中位随访8个月时39%出现肝功能障碍,肝功能障碍组中位剩余肝体积1002.1 cc低于肝功能正常组的1233 cc(p=0.02)。基线CT剩余体积低与肝功能障碍相关,Child-Pugh A患者生存率高于Child-Pugh B,基线MELD-Na评分较高与死亡相关。
要点
- 基线CT剩余肝体积低与TACE后中位8个月发生肝功能障碍相关(1002.1 cc vs 1233 cc,p=0.02)。
- Child-Pugh A患者6、12、24个月生存率分别为100%、97%、97%,高于Child-Pugh B的86%、78%、78%(p=0.07)。
- 死亡患者基线MELD-Na评分中位数6.7高于存活者的4.1(p=0.09)。
核心结论
- 基线CT剩余体积低与中位8个月时肝功能障碍的发生相关。
- 基线Child-Pugh A患者生存率高于Child-Pugh B患者。
- 基线MELD-Na评分较高与死亡相关。
研究设计与样本
- 回顾性单臂单中心研究,基于前瞻性维护的数据库,纳入41例诊断为肝细胞癌并接受经动脉化疗栓塞的患者。
- 采用多期CT体积分析,分别于门静脉期和晚动脉期计算全肝体积和肿瘤体积,剩余体积以全肝体积减去肿瘤体积计算。
- 基线评估时测量Child-Pugh、MELD评分和MELD-Na评分。
- 研究终点包括肝功能障碍(新发腹水、脑病和/或死亡事件)和总生存率。
诊断标准与关键数值
- 肝功能障碍组中位剩余肝体积1002.1 cc(IQR 633-1077.1 cc),肝功能正常组中位剩余肝体积1233 cc(IQR 1018.7-1437.6 cc),p=0.02。
- 总生存率在30天、12个月、24个月分别为95%、90%、85%。
- Child-Pugh A患者6、12、24个月总生存率分别为100%、97%、97%,Child-Pugh B患者分别为86%、78%、78%,p=0.07。
- 死亡患者基线MELD-Na评分中位数6.7(IQR 5-14.2),存活患者为4.1(IQR 2.14-6.85),p=0.09。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To assess the association between baseline CT-based volumetric parameters and biochemical hepatic evaluations, such as, Child-Pugh, MELD score, and modified MELD-Na score, on the prediction of outcomes of patients with HCC undergoing transarterial chemoembolization (TACE).
MATERIALS AND METHODS: A retrospective of a prospectively maintained database, single arm, and single center study was performed including 41 patients with diagnosis of hepatocellular carcinoma treated with TACE. Study endpoints included liver dysfunction (new events of ascites, encephalopathy, and/or death) and overall survival rate. Multi-phase CT-based volumetric analysis was performed to calculate total liver volume and tumor volume using portal and late arterial phases, respectively. Residual volume was calculated subtracting the tumor volume minus the total liver volume. Child-Pugh, MELD score, and MELD-Na score were measured during the baseline evaluation.
RESULTS: At a median follow-up time of 8 months (IQR, 5-14), 16 patients (39%) were diagnosed with hepatic dysfunction. In patients with hepatic dysfunction, the median residual hepatic volume was 1002.1 cc (IQR, 633-1077.1 cc) compared to patients with normal liver function post-TACE with a median residual volume of 1233 cc (IQR, 1018.7-1437.6 cc) (p = 0.02). Survival analysis demonstrated an overall survival rate of 95%, 90%, 85% at 30 days, 12 months, and 24 months, respectively. The overall survival rate in patients with Child-Pugh A was 100%, 97%, and 97% at 6, 12, and 24 months, respectively; compared to patients with Child Pugh B with an overall survival of rate of 86%, 78%, and 78% at 6, 12, and 24 months, respectively (p = 0.07). Median baseline MELD-Na score was higher in patients that died during the study period compared to patients that survived (6.7 [IQR, 5-14.2] versus 4.1 [IQR, 2.14-6.85]) (p = 0.09).
CONCLUSION: Low baseline CT-based residual volume is associated with the occurrence of hepatic dysfunction at a median time of 8 months. Baseline Child-Pugh A patients were found to have higher survival rate than Child-Pugh B. Interestingly, higher baseline MELD-Na score was associated with mortality.
引用
- Timaran Montenegro DE, Torres Ramirez CA, Mateo C YS, et al. CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. Acad Radiol. 2019. PMID: 31575476. doi:10.1016/j.acra.2019.09.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。